LeonaBio

LONA - LeonaBio • Financials

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
12/2018
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2019
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2020
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2021
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2022
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12/2023
0
-124
-
0%
L
439
L
-147
-
-111
-0
0
-112
0
0
-
-
12/2024
0
-100
-
0%
L
451
L
-51
-
-108
-0
0
-108
0
0
-
-
12/2025
0
-101
-
0%
L
540
L
-88
-
-52
0
82
-52
0
0
-
-